Introduction
Lung transplant is the only available treatment for patients with various end-stage lung diseases. However, rejection is a common complication faced by the lung transplant recipient (LTR) and a major impediment to long-term survival. 1, 2 Proinflammatory cytokines play an important role in the pathogenesis of rejection. 3 In the context of transplant, the proinflammatory cytokine tumor necrosis factor (TNF)-α is involved in acute graft rejection. The production of TNF-α from the activity of macrophages, natural killer cells, and T cells in the microenvironment of the graft is mainly regulated by single nucleotide polymorphisms (SNPs) in promoter regions at gene level. 4 Many studies have demonstrated an association between SNP of TNF-α-308 G/A and transplant rejection. [5] [6] [7] The major histocompatibility complex (MHC) is a genetic system of more than 70 known genes on the short arm of chromosome. 6 Typing of class I and class II MHC genes has been used to define the genetic basis of immune responses, such as rejection. 8 Large studies have indicated that donor-recipient matching at the HLA-A, -B and -DRB1 alleles offers the highest likelihood of survival. 9 Linkage disequilibrium (LD), the association in populations between genes at linked loci, has achieved a high degree of prominence in recent years, mainly because of its use in identifying and cloning genes of medical importance. 10 Many studies have shown that TNF-α was associated with conserved MHC haplotypes in European, Asian, and Australian aboriginal donors. [11] [12] [13] In other races and geographically distinct populations, these associations are different. For example, Chinese people in Taiwan with the TNF-α-308 A allele have been shown to have high antigen frequency of HLA-A*33 and -B*58. 14 However, few studies have reported on the association between TNF-α-308 G/A and the HLA-A, -B, and -DRB1 loci in mainland China.
In the present study, we examined the linkage disequilibrium between TNF-a-308 G/A and HLA alleles in LTRs of the Han nationality from East China. We also evaluated the correlation between TNF-α-308 G/A and the onset of acute rejection after lung allograft transplant.
Materials and Methods

Patients
All lung transplant recipients of Han nationality who were admitted into our hospital between August 2004 and July 2011 were included in the present study. According to the presence or absence of acute rejection (AR) episodes, the patients were divided into 2 groups: an AR group and a non-AR group. Acute rejection was defined as a biopsy indicative of rejection within the first 4 to 6 weeks after lung transplant, according to International Society for Heart and Lung Transplantation (ISHLT) criteria. 15 All protocols were approved by the ethics committee of the institution before the study began, and the protocols conformed with the ethical guidelines of the 1975 Helsinki Declaration. Written, informed consent was obtained from all patients.
Isolation of DNA
Peripheral blood samples were collected from the patients in tubes containing EDTA-K2 as an anticoagulant. Patients' DNA was extracted with Wizard genomic DNA purification kit (USA Promega Corporation, Madison, WI, USA) following manufacturer instructions.
Human leukocyte antigen allele genotyping
The HLA-A, -B, and -DRB1 alleles of the LTRs were examined by the polymerase chain reactionsequence specific primer (PCR-SSP) technique with PROTRANS HLA-A*/B*/DRB1* kit (ProTrans International, Indianapolis, IN, USA) following the manufacturer's instructions. In summary, a 280 μL buffer D, 560 μL buffer Y, 200 μL genomic DNA (75 ng/μL), and 32.5 U Taq DNA polymerase were mixed in a 1.5 mL centrifuge tube.
This DNA Master mix was dispensed into 96-well trays prealiquoted with primers and amplified in a thermocycler (9600 Thermal Cycler; Perkin-Elmer, Waltham, MA, USA). Thermocycling conditions were as follows: 1 cycle at 96°C for 130 seconds and 63°C for 60 seconds; then 9 cycles at 96°C for 10 seconds and 63°C for 60 seconds; followed by 20 cycles at 96°C for 10 seconds, 59°C for 50 seconds, and 72°C for 30 seconds. The amplified product was electrophoresed on a 2% agarose gel.
Results were interpreted on the basis of a positive amplification band. Each tube had an internal positive control band to check the integrity of the polymerase chain reaction.
tumor necrosis factor-α-308 G/A polymorphism genotyping The SNPs of TNF-α-308 were examined by the PCR-SSP method, using the Cytokine Genotyping Primer Pack (One Lambda, Inc, Canoga Park, CA, USA). To summarize this method, 19 μL genomic DNA (50-100 ng/μL) was mixed with 140 μL buffer D and 5 U Taq DNA polymerase.
As with the HLA DNA mixture, the TNF-α-308 DNA Master mix was dispensed into 96-well trays prealiquoted with primers and amplified in a PerkinElmer 9600 Thermal Cycler. Thermocycling conditions were as follows: 10 cycles at 94°C for 10 seconds and 65°C for 60 seconds, followed by 20 cycles at 94°C for 10 seconds, 61°C for 50 seconds, and 72°C for 30 seconds. The amplified products were electrophoresed on 2% agarose gel, and the typing results were interpreted using the worksheet provide with the product.
Statistical analyses
Statistical analyses were performed with SPSS software (SPSS: An IBM Company, version 15.0, IBM Corporation, Armonk, New York, USA). Deviation of the TNF-α gene from Hardy-Weinberg equilibrium was evaluated using the chi-square test. Allele and genotype frequencies were calculated in patients by direct gene counting. Possible association of TNF-α-308 G/A alleles with HLA-A, -B, and -DRB1 alleles was assessed by the chi-square test or the Fisher exact test. The frequencies of genotypes and alleles in the AR and non-AR group also were compared by the chi-square test or the Fisher exact test.
The d is an LD measure, if the d differs significantly from zero, LD is said to exist. The haplotype frequency (p ab ) was calculated using the following formula: p ab = number of observed haplotypes/2N(n, the number of samples). 
Results
A total of 106 LTRs were included in the present study. The patients consisted of 26 females and 80 males, with an age range from 17 to 73 years. The number of patients in the AR and non-AR groups were 15 and 76 respectively after excluding missing information.
Single nucleotide polymorphisms of tumor necrosis factor-α-308 and human leukocyte antigen -A, B, DrB1
Among the 106 LTRs, 80 (75.5%) patients had the G/G genotype, 25 (23.6%) had the G/A genotype, and 1 (0.9%) had the A/A genotype. The genotype distribution of TNF-α-308 A/G was in Hardy-Weinberg equilibrium in the LTRs (chi square = 0.3952, P = .53). The allele frequencies of HLA-A*2, -A*33, -B*58, and -DRB1*03 were 32.55% (28/212), 13.21% (69/212), 12.74% (27/212), and 8.96% (19/212) .
linkage disequilibrium between tumor necrosis factor-α-308 G/A and human leukocyte antigen-A* alleles The frequency of the HLA-A*33 allele in the 106 LTRs was 13.21% (28/212). Among the LTRs, 77.78% (21/27) had the TNF-a-308 A allele, and 3.78% (7/185) had the TNF-α-308 G allele, associated with HLA-A*33-a difference that is statistically significant (P < .01; Table 1 ). Analysis showed a positive LD between HLA-A*33 and TNF-α-308 A (d'=0.7443; Table 2 ). Similarly, 98.55% (67/68) of LTRs with HLA-A*2 had TNF-α-308 G, and only 1.45% (1/68) of LTRs with HLA-A*2 LTRs had TNF-α-308 A. Analysis showed a positive LD between HLA-A*2 and TNF-α-308 G (d'=0.8874; Table 2 ).
linkage disequilibrium between tumor necrosis factor-α-308 G/A and human leukocyte antigen -B* alleles As shown in Table 1 , the TNF-α-308 A allele was associated with HLA-B*58 in all of the LTRs, and the TNF-α-308 G allele was associated with HLA-B*58 in none of the LTRs-a difference that is statistically (Table 2) .
linkage disequilibrium between tumor necrosis factor-α-308 G/A and human leukocyte antigenDrB1* alleles In 59.26% (16/27) of LTRs with the TNF-α-308 A allele-and in 1.62% (3/185) of LTRs with the TNF-α-308 G allele-these alleles were associated with HLA-DRB1*03. This difference was statistically significant (P < .01; Table 1 ). Analysis showed that TNF-α-308 A was in LD with HLA-DRB1*03, with a d' value of 0.8199 (Table 2) .
linkage disequilibrium between tumor necrosis factor-α-308 G/A and human leukocyte antigen haplotypes Table 3 correlation between tumor necrosis factor-α-308-A subtype and acute rejection The differences of TNF-α-308 genotype within and between the AR and non-AR groups were further analyzed in 91 of the 106 LTRs. The results are shown in Table 4 . Genotype distribution of TNF-α-308 G/A was in Hardy-Weinberg equilibrium in both the AR group (chi-square=0.9735, P = .33) and the non-AR group (chi-square=1.21, P = .27). The overall incidence of acute rejection in both groups was 16.48% (15/91). Differences in TNF-α-308 genotype and allele distribution between the AR and non-AR group did not reach significance.
Discussion
The TNF-α gene is located on chromosome 6p21. 3 within the group of class III genes of the MHC. 16, 17 Strong LD between the HLA alleles and the TNF-α-308 G/A region has been identified by studying autoimmune associated diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and insulin-dependent diabetes mellitus. 18, 19 However, variations in the associations between HLA alleles and the TNF-α-308 G/A region have been confirmed among different races and populations.
In white populations, the TNF-α-308 A allele is associated with the ancestral HLA-A1-B8-DR3 haplotype, which confers susceptibility to many autoimmune diseases. 20, 21 In Gambian populations, TNF-α-308 A is carried without HLA-B*8, -B*58, or -DRB1*03. 22 In many Indian donors, TNF-α-308 A is associated with the Asian diabetogenic 58.1AH (HLA-A*33-B*58-DRB1*03). However, another Indian haplotype, characterized by HLA-B*8 and -DRB1*03, does not include TNF-α-308 A. 23 In Chinese from Taiwan, TNF-α-308A is associated with the haplotype of HLA-A*33-B*58-Cw*10. 14 In African-Americans from the Southeastern United States and in Mexican Mestizo, the TNF-α-308 A allele is not in LD with any HLA-DR alleles. 24, 25 Our data show that the HLA-A*33, -B*58, and -DRB1*03 alleles were in LD with TNF-α-308 A (d' = 0.7443, 1.000, 0.8199), and the HLA-A*2 allele was in LD with TNF-α-308 G (d' = 0.8874). Our data also showed that the HLA-A*33-DRB1*03 and HLA-B*58-DRB1*03 haplotypes were in LD with TNF-α-308 A-91.67% LTRs with the HLA-A*33-DRB1*03 haplotype, and all LTRs with the HLA-B*58-DRB1*03 haplotype, had the TNF-α-308 A allele. In light of these data, it is clear Table 2 . d, is a linkage disequilibrium measure that the TNF-α-308 A allele was in complete LD with HLA-B*58 in our Han population. TNF-α-308 A is a rare allele. In African-Americans from the Southeastern United States, the frequency of this allele is 14.4%, and in individuals of African-Caribbean descent living in Boston, its frequency is 13%. 24, 26 These TNF-α-308 A frequencies are similar to those reported in Africans from Gambia (16%, 17%), 27, 28 Malawi (12%, 11%), 26, 28 and Nigeria (13%). 26 By contrast, a study based on the largely white Western Australian Bone Marrow donor registry showed the frequency of individuals with TNF-α-308 A reached 34%. 29 Our data show the frequency of TNF-α-308 A in the Han nationality to be 12.74%. Because TNF-α-308 A was in complete LD with the HLA-B*58 allele in our population, the frequency of HLA-B*58 from 498 individuals which have been typed for HLA was substituted for the accurate frequency of TNF-α-308A, which was 7.33% (73/996). The frequency of the TNF-α-308 A allele in our Han population was similar to that reported from Tanzania (9%) (chi-square = 1.65, P > .05). 30 TNF-α-308 G/A is the binding site of activating protein-2 transcription factors. Compared to TNF-α-308 G, the TNF-α-308 A allele has been shown to increase the plasma cytokine level and to correlate with high in vitro TNF-α gene transcription and expression. [31] [32] [33] It also has been demonstrated that the TNF-α-308 A allele could increase the risk of acute rejection. 5, [34] [35] [36] [37] Interestingly, HLA-matched allogeneic donorrecipient pairs often are mismatched for microsatellite markers in the class III region, leading to complications after allogeneic hematopoietic stem cell transplants. 38, 39 These findings suggest that there are genes in the MHC other than HLA, such as TNF-α, that affect transplant outcome. Therefore, SNPs of TNF-α-308 might be important biomarkers for the prognosis or prediction of therapy response after transplant. 40 However, we did not reach such a conclusion in our study. Because of the small sample size of LTRs with TNF-α-308 A and the retrospective nature and short follow-up of our study, it would be necessary to enlarge the LTR sample size for further analysis of this matter.
In summary, our study showed that the TNF-α-308 G/A polymorphism was strongly associated with the HLA-A*2, -A*33, -B*58, and -DRB1*03 alleles in LTRs of the Han nationality from East China. Notably, the TNF-α-308 A allele was in complete LD with the HLA-B*58 allele. Genotyping of HLA can help to identify individuals carrying the "high-inflammatory" TNF-α-308 A allele, which may be beneficial for reducing or preventing the development of rejection after lung transplant. However，in our study, the TNF-α-308 A subtype likely had no correlation with the onset of acute rejection after lung transplant. The clinical relevance of the TNF-α-308 G/A polymorphism requires further research with larger sample sizes. 
